Advances in dendritic cell-based therapeutic vaccines for cervical cancer

被引:32
作者
Bellone, Stefania
Pecorelli, Sewio
Cannon, Martin J.
Santin, Alessandro D.
机构
[1] Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72205 USA
[2] Univ Brescia, Dept Obstet & Gynecol, Brescia, Italy
[3] Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA
关键词
cervical cancer; cytotoxic T lymphocyte; dendritic cell; E7; human parillomavirus; immunosuppression; immunotherapy;
D O I
10.1586/14737140.7.10.1473
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cervical cancer is the second leading cause of cancer death among women worldwide and remains an important health problem for women, especially in underserved and minority groups in industrially developed nations. Although radical surgery and radiotherapy represent effective modalities of treatment for invasive cervical cancer, up to 35% of these patients overall will develop recurrent/metastatic disease for which treatment results remain poor. Novel therapeutic strategies that are effective in reducing the risk of recurrence/metastatic disease are still needed desperately. Human papillomavirus (HPV) infection represents the most important risk factor for the development of cervical dysplasia and cervical cancer. Since HPVE6 and E7 oncoproteins are constantly expressed in these lesions, these foreign proteins represent ideal tumor-specific target antigens for immunotherapy of cervical cancer. Recently, the recognition of dendritic cells (DC) as powerful antigen-presenting cells, capable of inducing primary T-cell responses in vitro and in vivo, has generated widespread interest in DC-based immunotherapy of several human malignancies. This review summarizes the therapeutic clinical trials and the different preclinical research strategies that are under investigation, with a particular emphasis on the use of autologous DC-pulsed HPV16 or 18 E7 oncoproteins as therapeutic vaccines against cervical cancer.
引用
收藏
页码:1473 / 1486
页数:14
相关论文
共 131 条
  • [1] AIBA S, 1986, CANCER, V58, P1246, DOI 10.1002/1097-0142(19860915)58:6<1246::AID-CNCR2820580612>3.0.CO
  • [2] 2-E
  • [3] Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope
    Alexander, M
    Salgaller, ML
    Celis, E
    Sette, A
    Barnes, WA
    Rosenberg, SA
    Steller, MA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (06) : 1586 - 1593
  • [4] COMPARISON OF HUMAN-LEUKOCYTE ANTIGEN DR-DQ DISEASE ASSOCIATIONS FOUND WITH CERVICAL DYSPLASIA AND INVASIVE CERVICAL-CARCINOMA
    APPLE, RJ
    BECKER, TM
    WHEELER, CM
    ERLICH, HA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (06): : 427 - 436
  • [5] HLA DR-DQ ASSOCIATIONS WITH CERVICAL-CARCINOMA SHOW PAPILLOMAVIRUS-TYPE SPECIFICITY
    APPLE, RJ
    ERLICH, HA
    KLITZ, W
    MANOS, MM
    BECKER, TM
    WHEELER, CM
    [J]. NATURE GENETICS, 1994, 6 (02) : 157 - 162
  • [6] IMMUNE FUNCTION IN MALIGNANT CERVICAL NEOPLASIA - A MULTIPARAMETER ANALYSIS
    BALARAM, P
    PILLAI, MR
    PADMANABHAN, TK
    ABRAHAM, T
    HAREENDRAN, NK
    NAIR, MK
    [J]. GYNECOLOGIC ONCOLOGY, 1988, 31 (03) : 409 - 423
  • [7] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252
  • [8] Regulatory T cells in ovarian cancer: Biology and therapeutic potential
    Barnett, B
    Kryczek, I
    Cheng, P
    Zou, WP
    Curiel, TJ
    [J]. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 54 (06) : 369 - 377
  • [9] Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
    Bass, KK
    Mastrangelo, MJ
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (01) : 1 - 12
  • [10] Help for cytotoxic-T-cell responses is mediated by CD40 signalling
    Bennett, SRM
    Carbone, FR
    Karamalis, F
    Flavell, RA
    Miller, JFAP
    Heath, WR
    [J]. NATURE, 1998, 393 (6684) : 478 - 480